Iomai Corporation, a developer of vaccines and immunostimulants delivered to the skin, now intends to offer 5.0 million shares at a range of $7 to $9. The company originally planned to offer 6.25 million shares at a range of $11 to $13. UBS Investment Bank and SG Cowen are the joint book runners on the deal. Timing is day-to-day.
